Gerald Lewis
Psychiatric/Mental Health · Merrillville, INNPI 1639279177
Payments from drug & device makers
Across 1,542 payments — averaging $217.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$131K
- AbbVie$63K
- Otsuka America Pharmaceutical, Inc.$55K
- Axsome Therapeutics, Inc.$41K
- Johnson & Johnson$25K
- Almatica Pharma LLC$6K
- plus $15K from 33 others
What the payments were for
- Consulting fees$46,07014%
- Speaking & faculty fees$249,32974%
- Travel & lodging$9,0363%
- Food & beverage$30,9899%
- Education$2830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$128,164
- VRAYLAR$59,833
- Auvelity$39,009
- REXULTI$26,627
- ABILIFY MAINTENA$23,483
- SPRAVATO$22,813
- ABILIFY ASIMTUFII$16,722
- LOREEV XR$5,400
- Azstarys$1,103
- CAPLYTA$607
- LYBALVI$480
- ARISTADA$480
- LUMRYZ$255
- INVEGA SUSTENNA$249
- XYWAV$229
- ARISTADA INITIO$120
- QUVIVIQ$114
- INVEGA TRINZA$110
How this compares
$335,706 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $240,153 |
| VraylarCariprazine Hcl | 102 | $158,770 |
| AustedoDeutetrabenazine | 22 | $155,047 |
| SpravatoEsketamine Hcl | 106 | $130,821 |
| CaplytaLumateperone Tosylate | 71 | $117,611 |
| TrintellixVortioxetine Hydrobromide | 97 | $61,460 |
| AuvelityDextromethorphan Hbr/Bupropion | 57 | $59,096 |
| RexultiBrexpiprazole | 33 | $54,872 |
| FanaptIloperidone | 18 | $32,313 |
| BelsomraSuvorexant | 59 | $27,976 |
| VyvanseLisdexamfetamine Dimesylate | 59 | $24,293 |
| Aripiprazole | 183 | $17,871 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 169 | $16,916 |
| QelbreeViloxazine Hcl | 19 | $14,911 |
| Chlorpromazine Hcl | 31 | $12,410 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $131,172 | $240,15324 claims |
| AbbVieVraylar | $62,950 | $158,770102 claims |
| Johnson & JohnsonSpravato | $24,960 | $130,821106 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,899 | $117,61171 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $649 | $85,753156 claims |
| Axsome Therapeutics, Inc.Auvelity | $40,665 | $59,09657 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $55,206 | $54,87233 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $522 | $32,31318 claims |
| MerckBelsomra | $220 | $27,97659 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $1,771 | $14,91119 claims |
| Almatica Pharma LLCLoreev Xr | $5,814 | $10,29923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Merrillville
- Kimberly SirkMerrillville$16K
- Helen MunnMerrillville$13K
- Sandra SperlingMerrillville$8K
- Jazmine QuinteroMerrillville$6K
- Brooke KempfTerre Haute$1.1M
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.